Obesity raises the risk of type 2 diabetes and cardiovascular disease. That's why this new analysis matters. A post-hoc analysis showed our oral obesity medicine was associated with reductions in predicted 10-year risk of both conditions — with reductions seen across all doses. See our press release at the link in bio. #EASD2026